Physician profile
James Chong
NPI 1538130828
$14,939.15
in general payments reported to CMS, 2019-2025
48 companies · $2,993 in 2025
The $2,993 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,681 · 2020: $1,255 · 2021: $2,294 · 2022: $2,423 · 2023: $2,349 · 2024: $1,945 · 2025: $2,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,140 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,140.21 |
| Education | $146.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,155.35 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,367.37 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,359.59 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $956.12 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $944.90 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $676.46 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $452.51 | 2019-2024 | Dificid, Zinplava, Zerbaxa |
| Medtronic, INC. | $322.04 | 2022-2023 | Interstim |
| Cumberland Pharmaceuticals, INC. | $316.22 | 2019-2023 | Kristalose |
| Phathom Pharmaceuticals, INC. | $308.57 | 2024-2025 | Voquezna |
| Genzyme Corporation | $295.76 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $294.76 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $293.67 | 2019-2025 | |
| Allergan, INC. | $246.90 | 2019-2020 | |
| Ardelyx, INC. | $236.54 | 2022-2025 | Ibsrela |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $229.34 | 2021-2023 | |
| Lilly USA, LLC | $214.81 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $204.96 | 2019-2023 | Suflave |
| Ferring Pharmaceuticals INC. | $189.55 | 2019-2025 | Clenpiq |
| Celltrion USA INC. | $173.87 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $170.46 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $149.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $130.95 | 2019-2025 | |
| Ucb, INC. | $125.98 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $124.68 | 2019-2024 | Linzess |
| Redhill Biopharma INC. | $109.79 | 2020-2023 | Talicia |
| Romark Laboratories, Lc | $99.66 | 2019-2020 | |
| Vivus LLC | $96.59 | 2020-2025 | Pancreaze, Qsymia |
| Pharmacosmos Therapeutics INC. | $92.44 | 2023-2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $85.21 | 2022-2025 | Dupixent |
| Evoke Pharma, INC. | $63.60 | 2021-2023 | Gimoti |
| Aimmune Therapeutics, INC. | $51.43 | 2024 | |
| Endo Pharmaceuticals INC. | $40.92 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $40.72 | 2022-2023 | Valve Kits |
| Shire North American Group INC | $39.49 | 2019 | |
| Fresenius Kabi USA, LLC | $33.92 | 2023-2024 | Idacio |
| Boston Scientific Corporation | $33.61 | 2023 | |
| Alnylam Pharmaceuticals INC. | $29.75 | 2022 | |
| Amgen INC. | $22.69 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.57 | 2019 | |
| Genentech USA, INC. | $22.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.89 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $18.37 | 2024 | Exparel |
| Novo Nordisk INC | $16.08 | 2025 | Wegovy |
| Axonics, INC. | $15.63 | 2023 | Axonics |
| Daiichi Sankyo INC. | $15.16 | 2019 | |
| Lucid Diagnostics INC. | $14.08 | 2023 | |
| Pentax of America, INC. | $13.94 | 2024 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.